Hoth Therapeutics, which is developing topical treatments for eczema, raised $7.0 million by offering 1.25 million shares at $5.60, towards the low end of the range of $5.50 to $6.50. At $5.60, the company commands a market value of $57 million. Hoth Therapeutics plans to list on the Nasdaq under the symbol HOTH. Laidlaw & Company (UK) acted as sole bookrunner on the deal.
